BMRN Q4 2021 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$450M-0.5% YoY

Gross Profit

$330M73.4% margin

Operating Income

-$66M-14.6% margin

Net Income

-$58M-12.9% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

+10.0%

Cash Flow

Operating Cash Flow

$11M

Free Cash Flow

-$33M

Stock-Based Comp.

$44M

Balance Sheet

Total Assets

$6.0B

Total Liabilities

$1.7B

Stockholders' Equity

$4.3B

Cash & Equivalents

$587M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$450M	$452M	-0.5%
Gross Profit	$330M	$326M	+1.3%
Operating Income	-$66M	-$45M	-46.9%
Net Income	-$58M	$22M	-362.0%

Revenue Segments

Product

$435M97%

Royalty And Other

$15M3%